X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.487
-0.003 (-0.51%)
Jan 22, 2025, 2:19 PM EST - Market open
X4 Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 3.50, with a low estimate of 1.50 and a high estimate of 5.00. The average target predicts an increase of 618.98% from the current stock price of 0.49.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for XFOR stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +208.13% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $1.5 | Strong Buy | Maintains | $5 → $1.5 | +208.13% | Nov 14, 2024 |
| Stifel | Stifel | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +721.69% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +927.12% | Jun 28, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $5 | Buy | Reiterates | $5 | +927.12% | May 31, 2024 |
Financial Forecast
Revenue This Year
2.24M
Revenue Next Year
16.88M
from 2.24M
Increased by 652.72%
EPS This Year
-0.24
from -0.57
EPS Next Year
-0.54
from -0.24
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.8M | 24.7M | 136.2M | |||
| Avg | 2.2M | 16.9M | 63.4M | |||
| Low | 1.9M | 7.6M | 19.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 1,000.6% | 707.0% | |||
| Avg | - | 652.7% | 275.6% | |||
| Low | - | 240.9% | 14.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.15 | -0.30 | -0.25 | |||
| Avg | -0.24 | -0.54 | -0.33 | |||
| Low | -0.68 | -0.76 | -0.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.